Business
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued Growth and Raising 2026 Full Year Guidance – – Company to Host Investor Conference Call Today at 8:30 a.m. EST – BRIDGEWATER, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a diversified, global biopharmaceutical leader focused on expand
About this update from Amneal Pharmaceuticals, Inc.
[{"type":"image","alt":"Amneal Pharmaceuticals LLC","displaySize":"","headline":null,"caption":"Amneal Pharmaceuticals LLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/3f58c6fb731aca69660cfd5331ef1107"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D5k2pDlH1.f72pOlfEh1mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNQ--/https://media.zenfs.com/en/globenewswire.com/3f58c6fb731aca69660cfd5331ef1107","width":300,"height":89}},"lazy":false},{"type":"text","content":"– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity –","length":89,"tagName":"p"},{"type":"text","content":"– Transaction Accelerates Growth Profile and Diversification –","length":62,"tagName":"p"},{"type":"text","content":"– Preliminary Q1 Results Reflect Continued Growth and Raising 2026 Full Year Guidance –","length":87,"tagName":"p"},{"type":"text","content":"– Company to Host Investor Conference Call Today at 8:30 a.m. EST –","length":67,"tagName":"p"},{"type":"text","content":"BRIDGEWATER, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines, today announced that it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, LLC (“Kashiv”) in a transaction with consideration that includes $375 million of cash and $375 million of equity payable at closing, plus up to $350 million in potential payments based on the achievement of certain regulatory milestones, potential royalties based on commercial milestones, and funding of operations through closing.","length":677,"tagName":"p"},{"type":"text","content":"Kashiv is among a select group of U.S.-based companies with proven end-to-end biosimilars capabilities across development and manufacturing, and a robust pipeline. This transaction will establish a scaled, fully integrated global biosimilars platform at a pivotal moment, ahead of a more than $300 billion projected global biologics loss-of-exclusivity wave over the next decade, accelerating growth and meaningfully extending and diversifying Amneal’s long-term growth profile.","length":478,"tagName":"p"},{"type":"text","content":"“As biosimilar adoption accelerates and the ...